African Journal of
Pharmacy and Pharmacology

  • Abbreviation: Afr. J. Pharm. Pharmacol.
  • Language: English
  • ISSN: 1996-0816
  • DOI: 10.5897/AJPP
  • Start Year: 2007
  • Published Articles: 2173

Full Length Research Paper

Neostigmine modulates tularemia progression in BALB/c mice

Miroslav Pohanka1* and Oto Pavlis1,2    
1Faculty of Military Health Sciences, University of Defense, Trebesska 1575, 50001 Hradec Kralove, Czech Republic. 2Centre of Biological Defense, 561 66 Techonin, Czech Republic.    
Email: [email protected]

  •  Accepted: 29 February 2012
  •  Published: 08 May 2012


Neostigmine is a pseudo-irreversible inhibitor of enzyme acetylcholinesterase (AChE). We hypothesized link between neostigmine and cholinergic anti-inflammatory pathway via better availability of blood acetylcholine after AChE inhibition and consequent activation of nicotinic acetylcholine receptors. Owing to the expected mechanism of action, we expect significant impact of neostigmine on immunity. In the reported experiment, we used BALB/c mouse model and experimental infection with Francisella tularensis, a causative agent of tularemia. Interferon γ, interleukin 6 and mortality test are done for neostigmine doses of 8.00, 40.0 and 200 µg/kg. We proved significant decrease of both cytokines in course of neostigmine in a dose dependent manner. Neostigmine aggravates mortality caused by tularemia. Owing to the reported results, application of AChE inhibitors to patients suspected with tularemia or similar diseases can be considered as a life endangering therapy.


Key words: Inflammation, tularemia, alzheimer disease, myasthenia gravis, innate immunity.

  • Articles on Google by: